Dr. Mitchell B. Alden, DO

Dr. Alden practices at Pennridge Surgical Associates in Sellersville, Pennsylvania.

Dr. Alden's NPI, 1861474991, was assigned on November 15, 2005. Dr. Alden graduated from Pcom in 1989. Dr. Alden holds Pennsylvania license OS007766L.

Dr. Alden's primary practice is Pennridge Surgical Associates, at 915 Lawn Ave, Sellersville, PA 18960 in Bucks County. The practice phone is (215) 257-3697.

Dr. Alden's primary practice is Pennridge Surgical Associates in Sellersville, Pennsylvania. Dr. Alden is also affiliated with St. Luke's Grand View Hospital - Sellersville. The medical group on file is Alliance Cancer Specialists. Dmand AI also links Dr. Alden to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alden practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Alden's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Alden is board certified in medical oncology by the American Board of Internal Medicine. Dr. Alden is licensed in Pennsylvania.

Dmand AI lists arterial blot clot /embolism, breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT) and immune deficiency disease among the conditions Dr. Alden treats.

CMS data shows 108,025 Medicare services from Dr. Alden across 51 procedure codes in 2024, for 791 Medicare patients. Medicare paid $1,971,143 for them.

CMS counts 791 Medicare patients who saw Dr. Alden in 2024. The largest group is 65 to 74, with 324 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alden's median patient age at 74, with 49% women.

In 2024, Dr. Alden wrote 1,232 Medicare Part D claims for 276 patients. 65% of them were for generic drugs. CMS names the drug for 1,076 of them, across 29 drugs with 11 or more claims each, at $2,465,029 in total drug cost. In 2023, CMS named 956 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Alden for performance year 2024. Dr. Alden accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Alden. Dr. Alden's most frequent co-authors are Nabil Adra, MD, Leonard Joseph Appleman, MD and Charles David Blanke, MD.

Dmand AI links Dr. Alden to 25 clinical trials, 15 of them phase 3 studies. 14 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Non-Small-Cell Lung. National Cancer Institute (NCI) sponsors the most, 16.

CMS Open Payments shows 1,271 general payments to Dr. Alden from 110 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 95% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,559.

Dmand AI lists 1 award for Dr. Alden, most recently CMS Stage 1 EHR in 2014.

Dr. Alden graduated from Pcom in 1989. Dr. Alden is a member of ACP.

Dr. Alden is in network with 20 carriers, including Aetna, Blue Cross Blue Shield of Michigan and HCSC. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.